Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
Have you had success treating localized skin infections due to M. chelonae with single agent therapy in immunocompetent hosts?
Related Questions
Would you treat a brain abscess due to S. anginosus longer than one caused by another organism?
For which pediatric oncology patients do you start bacterial prophylaxis, inpatient or outpatient, and what is your antibiotic of choice?
How long would you continue intravenous suppressive therapy following surgical washout for a patient with an LVAD as destination therapy, found to have an outflow tract fluid collection secondary to fluoroquinolone-resistant pseudomonas aeruginosa?
Do you recommend to continue acyclovir to prevent HSV infection in an HIV patient with CD4 count more than 200 and with high viral load?
Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
What is your typical duration and route of treatment for a lytic lesion in the metaphysis of a long bone secondary to MSSA, i.e., a Brodie abscess, following debridement in an immunocompetent patient?
What approximate portion of men develop infertility following a mumps infection?
What is your preferred dosing of IV ganciclovir for CMV disease in immunocompromised patients?
How do you approach vaccination, particularly the use of live vaccines such as yellow fever, in a patient with rheumatoid arthritis receiving a TNF inhibitor who is planning travel to Africa?
When would you consider an all-oral regimen for patients with Whipple's disease instead of the typical parenteral treatment with ceftriaxone or meropenem followed by oral TMP/SMX?
